Jane Street Group, LLC Arvinas, Inc. Call Options Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$23.66 - $32.73 $432,978 - $598,959	18,300 New	18,300 $450,000
Q2 2022 Aug 16, 2022	SELL	$36.01 - $74.24 $1.09 Million - $2.24 Million	-30,200 Closed	0 $0
Q1 2022 May 17, 2022	SELL	$60.27 - $81.57 $126,567 - $171,297	-2,100 Reduced 6.5%	30,200 $2.03 Million
Q4 2021 Feb 15, 2022	BUY	$65.85 - $96.21 $355,589 - $519,533	5,400 Added 20.07%	32,300 $2.65 Million
Q3 2021 Nov 16, 2021	BUY	$73.2 - $107.87 $336,720 - $496,202	4,600 Added 20.63%	26,900 $2.21 Million
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $441,285 - $615,098	7,300 Added 48.67%	22,300 $1.72 Million
Q1 2021 May 18, 2021	SELL	$58.19 - $91.37 $221,122 - $347,206	-3,800 Reduced 20.21%	15,000 $992,000
Q4 2020 Feb 17, 2021	BUY	$20.19 - $84.93 $379,572 - $1.6 Million	18,800 New	18,800 $1.6 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.